8 employees
Pneumagen develops glycan targeted carbohydrate binding modules (CBMs) for respiratory tract infections ) and cancer.
2016
$10M
from 2 investors over 2 rounds
PNEUMAGEN LIMITED raised $10M on June 1, 2023
Investors: Scottish Enterprise
PNEUMAGEN LIMITED raised $5.2M on January 19, 2022